{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:30:55Z","timestamp":1790353855134,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104244"],"award-info":[{"award-number":["82104244"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.intimp.2025.114520","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T04:19:49Z","timestamp":1743221989000},"page":"114520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Identifying cardiovascular toxicity associated with sphingosine 1-phosphate receptor modulators: A case-control study based on the FDA adverse event reporting system"],"prefix":"10.1016","volume":"153","author":[{"given":"Ying","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingmin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangrui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujie","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyuan","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.intimp.2025.114520_bb0005","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"Jama"},{"issue":"8 Suppl 3","key":"10.1016\/j.intimp.2025.114520_bb0010","first-page":"S3","article-title":"Sphingosine 1-phosphate (S1P): physiology and the effects of S1P receptor modulation","volume":"76","author":"Hla","year":"2011","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.intimp.2025.114520_bb0015","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40263-021-00798-w","article-title":"Sphingosine 1-phosphate receptor modulators for multiple sclerosis","volume":"35","author":"Roy","year":"2021","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1016\/j.intimp.2025.114520_bb0020","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S1474-4422(21)00063-6","article-title":"Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances","volume":"20","author":"Bar-Or","year":"2021","journal-title":"Lancet Neurol."},{"issue":"6463","key":"10.1016\/j.intimp.2025.114520_bb0025","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar5551","article-title":"Sphingosine 1-phosphate: lipid signaling in pathology and therapy","volume":"366","author":"Cartier","year":"2019","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.intimp.2025.114520_bb0030","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40265-020-01431-8","article-title":"Sphingosine 1-phosphate receptor modulator therapy for multiple sclerosis: differential downstream receptor Signalling and clinical profile effects","volume":"81","author":"Chun","year":"2021","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.intimp.2025.114520_bb0035","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.bbalip.2013.11.001","article-title":"Second generation S1P pathway modulators: research strategies and clinical developments","volume":"1841","author":"Bigaud","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"issue":"10306","key":"10.1016\/j.intimp.2025.114520_bb0040","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0140-6736(21)00244-0","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions","volume":"398","author":"McGinley","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.intimp.2025.114520_bb0045","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2217\/cer-2019-0169","article-title":"Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis","volume":"9","author":"Swallow","year":"2020","journal-title":"J. Comp. Eff. Res."},{"issue":"9","key":"10.1016\/j.intimp.2025.114520_bb0050","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamacardio.2022.2333","article-title":"Joint genetic inhibition of PCSK9 and CETP and the association with coronary artery disease: a factorial Mendelian randomization study","volume":"7","author":"Cupido","year":"2022","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.intimp.2025.114520_bb0055","doi-asserted-by":"crossref","DOI":"10.1177\/1759091421991771","article-title":"Sex effect on cardiac damage in mice with experimental autoimmune encephalomyelitis","volume":"13","author":"Wu","year":"2021","journal-title":"ASN Neuro"},{"key":"10.1016\/j.intimp.2025.114520_bb0060","author":"FDA Adverse Event Reporting System (FAERS) Quarterly Data Extract Files"},{"issue":"3","key":"10.1016\/j.intimp.2025.114520_bb0065","article-title":"A standardized dataset of a spontaneous adverse event reporting system","volume":"10","author":"Khaleel","year":"2022","journal-title":"Healthcare (Basel)"},{"issue":"7","key":"10.1016\/j.intimp.2025.114520_bb0070","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00002018-200730070-00011","article-title":"Bayesian confidence propagation neural network","volume":"30","author":"Bate","year":"2007","journal-title":"Drug Safety Int. J. Med. Toxicol. & Drug Exp."},{"issue":"1","key":"10.1016\/j.intimp.2025.114520_bb0075","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"8","key":"10.1016\/j.intimp.2025.114520_bb0080","doi-asserted-by":"crossref","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: Nonparametric preprocessing for parametric causal inference","volume":"42","author":"Ho","year":"2011","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.intimp.2025.114520_bb0085","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"key":"10.1016\/j.intimp.2025.114520_bb0090","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"Bmj"},{"issue":"2","key":"10.1016\/j.intimp.2025.114520_bb0095","doi-asserted-by":"crossref","first-page":"64","DOI":"10.35566\/jbds\/v3n2\/wang","article-title":"Conducting Meta-analyses of proportions in R","volume":"3","author":"Wang","year":"2023","journal-title":"J. Behav. Data Sci."},{"issue":"5","key":"10.1016\/j.intimp.2025.114520_bb0100","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ahj.2014.06.028","article-title":"Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications","volume":"168","author":"Camm","year":"2014","journal-title":"Am. Heart J."},{"issue":"11","key":"10.1016\/j.intimp.2025.114520_bb0105","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s40262-023-01308-5","article-title":"Clinical pharmacokinetics of Ponesimod, a selective S1P1 receptor modulator, in the treatment of multiple sclerosis","volume":"62","author":"Kruger","year":"2023","journal-title":"Clin. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.intimp.2025.114520_bb0110","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1476-5381.2012.02061.x","article-title":"The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate","volume":"167","author":"Gergely","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.intimp.2025.114520_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1431380","article-title":"Long-term effects of siponimod on cardiovascular and autonomic nervous system in secondary progressive multiple sclerosis","volume":"15","author":"Constantinescu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2025.114520_bb0120","first-page":"61","article-title":"Ponesimod in the treatment of relapsing forms of multiple sclerosis: an update on the emerging clinical data","volume":"12","author":"Ruggieri","year":"2022","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"issue":"11","key":"10.1016\/j.intimp.2025.114520_bb0125","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial","volume":"18","author":"Cohen","year":"2019","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.intimp.2025.114520_bb0130","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaneurol.2021.0405","article-title":"Ponesimod compared with Teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial","volume":"78","author":"Kappos","year":"2021","journal-title":"JAMA Neurol."},{"issue":"11","key":"10.1016\/j.intimp.2025.114520_bb0135","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/j.clinthera.2015.09.006","article-title":"Effects of therapeutic and Supratherapeutic doses of Siponimod (BAF312) on cardiac repolarization in healthy subjects","volume":"37","author":"Shakeri-Nejad","year":"2015","journal-title":"Clin. Ther."},{"key":"10.1016\/j.intimp.2025.114520_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104827","article-title":"Index of cardiac-electrophysiological balance in relapsing-remitting multiple sclerosis patients treated with fingolimod","volume":"76","author":"Gunay-Polatkan","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.intimp.2025.114520_bb0145","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bcpt.12336","article-title":"Effect of Ponesimod, a selective S1P1 receptor modulator, on the QT interval in healthy individuals","volume":"116","author":"Hoch","year":"2015","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"2","key":"10.1016\/j.intimp.2025.114520_bb0150","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/psp4.12580","article-title":"Concentration-QTc modeling of Ozanimod's major active metabolites in adult healthy subjects","volume":"10","author":"Briggs","year":"2021","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2025.114520_bb0155","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1124\/jpet.116.233205","article-title":"S1P signaling and De novo biosynthesis in blood pressure homeostasis","volume":"358","author":"Cantalupo","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.intimp.2025.114520_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.861885","article-title":"Multiple sclerosis and the risk of cardiovascular diseases: a Mendelian randomization study","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2025.114520_bb0165","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1080\/1061186X.2024.2309577","article-title":"Insight into modulators of sphingosine-1-phosphate receptor and implications for cardiovascular therapeutics","volume":"32","author":"Xie","year":"2024","journal-title":"J. Drug Target."},{"key":"10.1016\/j.intimp.2025.114520_bb0170","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419878324","article-title":"Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results","volume":"12","author":"Cohen","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.intimp.2025.114520_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2024.106682","article-title":"Signaling roles of sphingolipids in the ischemic brain and their potential utility as therapeutic targets","volume":"201","author":"Mohamud Yusuf","year":"2024","journal-title":"Neurobiol. Dis."},{"issue":"10","key":"10.1016\/j.intimp.2025.114520_bb0180","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1177\/13524585221083194","article-title":"Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: analysis of EXPAND core and extension data up to >5years","volume":"28","author":"Cree","year":"2022","journal-title":"Mult. Scler."},{"issue":"10127","key":"10.1016\/j.intimp.2025.114520_bb0185","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925005107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925005107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T21:00:28Z","timestamp":1744491628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925005107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":37,"alternative-id":["S1567576925005107"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114520","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identifying cardiovascular toxicity associated with sphingosine 1-phosphate receptor modulators: A case-control study based on the FDA adverse event reporting system","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114520","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114520"}}